



## **Crucell announces STAR™ Research License Agreement**

**Leiden, The Netherlands, April 6, 2006** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) announced today that it has signed a non-exclusive STAR™ research license agreement for the production of monoclonal antibodies with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation. Financial details were not disclosed.

### **For further information please contact:**

**Crucell N.V.**

Leonard Kruimer

Chief Financial Officer

Tel. +31-(0)71-524 8722

[l.kruimer@crucell.com](mailto:l.kruimer@crucell.com)